These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 25287169

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
    Wang YY, Qi LN, Zhong JH, Qin HG, Ye JZ, Lu SD, Ma L, Xiang BD, Li LQ, You XM.
    Sci Rep; 2017 Feb 09; 7():42199. PubMed ID: 28181486
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.
    Xie C, Ye X, Zeng L, Zeng X, Cao D.
    J Gastroenterol; 2023 Oct 09; 58(10):1030-1042. PubMed ID: 37500927
    [Abstract] [Full Text] [Related]

  • 6. Prognostic Significance of 14-3-3ε, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
    Wu CY, Jan YJ, Ko BS, Wu YJ, Wu YJ, Liou JY.
    Anticancer Res; 2018 Dec 09; 38(12):6855-6863. PubMed ID: 30504401
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
    Matkowskyj KA, Bai H, Liao J, Zhang W, Li H, Rao S, Omary R, Yang GY.
    Hum Pathol; 2014 Apr 09; 45(4):834-43. PubMed ID: 24656094
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
    Tsuzura H, Genda T, Sato S, Murata A, Kanemitsu Y, Narita Y, Ishikawa S, Kikuchi T, Mori M, Hirano K, Iijima K, Wada R, Ichida T.
    Int J Mol Sci; 2014 Apr 17; 15(4):6556-68. PubMed ID: 24747592
    [Abstract] [Full Text] [Related]

  • 16. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
    Jin GZ, Yu WL, Dong H, Zhou WP, Gu YJ, Yu H, Yu H, Lu XY, Xian ZH, Liu YK, Cong WM, Wu MC.
    J Hepatol; 2013 Sep 17; 59(3):510-7. PubMed ID: 23665285
    [Abstract] [Full Text] [Related]

  • 17. AKR1B10 expression characteristics in hepatocellular carcinoma and its correlation with clinicopathological features and immune microenvironment.
    Ma LN, Ma Y, Luo X, Ma ZM, Ma LN, Ding XC.
    Sci Rep; 2024 May 27; 14(1):12149. PubMed ID: 38802416
    [Abstract] [Full Text] [Related]

  • 18. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
    Schmitz KJ, Sotiropoulos GC, Baba HA, Schmid KW, Müller D, Paul A, Auer T, Gamerith G, Loeffler-Ragg J.
    Liver Int; 2011 Jul 27; 31(6):810-6. PubMed ID: 21645211
    [Abstract] [Full Text] [Related]

  • 19. Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy.
    Kim SH, Ahn S, Park CK.
    Hepatobiliary Pancreat Dis Int; 2012 Feb 27; 11(1):51-9. PubMed ID: 22251470
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients.
    Fang CY, Lin YH, Chen CL.
    J Oral Pathol Med; 2019 Sep 27; 48(8):712-719. PubMed ID: 31237374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.